Facebook
Britain's News Portal
Around The Clock
BREAKING
Loading latest headlines…

US Abortion Pill Maker Appeals Ban on Mail-Order Access to Supreme Court

Danco Laboratories has filed an emergency appeal to the US Supreme Court, seeking to overturn a lower court's decision that would mandate in-person examinations for abortion pill prescriptions. This legal challenge follows a temporary reinstatement of the in-person requirement by the fifth US circuit court of appeals.

  • Danco Laboratories, a maker of mifepristone, has appealed to the US Supreme Court.
  • The appeal seeks to halt a decision requiring in-person exams for abortion pill prescriptions.
  • The fifth US circuit court of appeals temporarily reinstated the in-person requirement.
  • The case centres on access to telemedicine for prescribing mifepristone.

Danco Laboratories, a manufacturer of the abortion pill mifepristone, has filed an emergency appeal with the US Supreme Court. The company is asking the highest court to intervene and halt a recent court decision that would necessitate an in-person examination before the medication can be prescribed. This request was made on Saturday, just hours after the fifth US circuit court of appeals temporarily reinstated the requirement for patients to be seen in person by a clinician.

The legal challenge focuses on the future of telemedicine provision for mifepristone, a drug used for medical abortions. The lower court's ruling, which Danco Laboratories is challenging, would effectively block telemedicine providers from prescribing the medication, thereby restricting access for many individuals across the United States. This move has significant implications for reproductive healthcare access, particularly in regions where in-person clinics may be scarce.

Mifepristone is a crucial component of medical abortion and has been approved by the US Food and Drug Administration (FDA) for over two decades. The ongoing legal battle highlights the contentious nature of abortion access in the US, following the overturning of Roe v. Wade. The FDA's previous actions to expand access to mifepristone, including allowing it to be dispensed by certified pharmacies and through mail order, are now under scrutiny.

In the UK, medical abortion services, including the use of mifepristone, are regulated by the Department of Health and Social Care. NHS guidelines and NICE recommendations underpin the provision of these services, ensuring they are safe and accessible within legal frameworks. While telemedicine for abortion care saw an expansion during the pandemic, the UK's approach is distinct from the US legal landscape, with different regulatory bodies and legal precedents.

It is important for readers to note that this article reports on legal developments in the United States and does not constitute medical advice. Anyone with concerns about their health or seeking information on abortion services in the UK should consult their GP or a qualified healthcare professional.

Why this matters: While this case is unfolding in the US, it reflects broader international debates around reproductive rights and access to healthcare. Developments in US law can sometimes influence discussions and policy considerations in other nations, including the UK, regarding medical services and regulatory oversight.

What this means for you: This story may affect patients, NHS access, appointments or local health services. If it relates to your care, check official NHS guidance or contact the relevant service for personal advice.

Related Articles

Get the news that matters.

Join thousands of readers getting the best of British news straight to their inbox.